Organovo Holdings, Inc. (ONVO): Price and Financial Metrics

Organovo Holdings, Inc. (ONVO): $1.71

0.03 (+1.79%)

POWR Rating

Component Grades








Add ONVO to Watchlist
Sign Up

Industry: Medical - Diagnostics/Research




#50 of 58

in industry

ONVO Price/Volume Stats

Current price $1.71 52-week high $3.72
Prev. close $1.68 52-week low $1.37
Day low $1.63 Volume 18,200
Day high $1.73 Avg. volume 79,508
50-day MA $1.94 Dividend yield N/A
200-day MA $1.92 Market Cap 14.90M

ONVO Stock Price Chart Interactive Chart >

ONVO Stock Summary

  • ORGANOVO HOLDINGS INC's market capitalization of $15,511,970 is ahead of only 6.67% of US-listed equities.
  • ONVO's price/sales ratio is 9.08; that's higher than the P/S ratio of 88.29% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.11 for ORGANOVO HOLDINGS INC; that's greater than it is for merely 9.25% of US stocks.
  • If you're looking for stocks that are quantitatively similar to ORGANOVO HOLDINGS INC, a group of peers worth examining would be WISH, HLGN, RAMP, SLGC, and ASAN.
  • Visit ONVO's SEC page to see the company's official filings. To visit the company's web site, go to

ONVO Valuation Summary

  • ONVO's price/earnings ratio is -1.3; this is 105.39% lower than that of the median Healthcare stock.
  • Over the past 137 months, ONVO's price/earnings ratio has gone up 74.4.

Below are key valuation metrics over time for ONVO.

Stock Date P/S P/B P/E EV/EBIT
ONVO 2023-05-23 9.2 0.7 -1.3 0.2
ONVO 2023-05-22 9.3 0.7 -1.4 0.2
ONVO 2023-05-19 9.2 0.7 -1.3 0.2
ONVO 2023-05-18 9.2 0.7 -1.3 0.2
ONVO 2023-05-17 9.0 0.7 -1.3 0.3
ONVO 2023-05-16 9.0 0.7 -1.3 0.3

ONVO Growth Metrics

    Its 3 year net cashflow from operations growth rate is now at 58.51%.
  • The 5 year revenue growth rate now stands at -48.09%.
  • The 3 year price growth rate now stands at -81.41%.
Over the past 70 months, ONVO's revenue has gone down $2,522,000.

The table below shows ONVO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 1.708 -9.216 -11.711
2022-09-30 1.577 -9.528 -11.947
2022-06-30 1.5 -9.454 -12.131
2022-03-31 1.5 -8.453 -11.448
2021-12-31 0 -9.026 -12.133
2021-09-30 0 -7.161 -11.144

ONVO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ONVO has a Quality Grade of D, ranking ahead of 17.68% of graded US stocks.
  • ONVO's asset turnover comes in at 0 -- ranking 440th of 680 Pharmaceutical Products stocks.
  • SYRS, DRNA, and CPHI are the stocks whose asset turnover ratios are most correlated with ONVO.

The table below shows ONVO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.000 NA -9.390
2021-03-31 0.000 NA -11.494
2020-12-31 0.000 NA -19.890
2020-09-30 0.011 0.956 -5936.667
2020-06-30 0.050 0.819 -9.301
2020-03-31 0.062 0.851 -4.771

Organovo Holdings, Inc. (ONVO) Company Bio

Organovo Holdings, Inc. focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company was founded in 2007 and is based in San Diego, California.

ONVO Latest News Stream

Event/Time News Detail
Loading, please wait...

ONVO Latest Social Stream

Loading social stream, please wait...

View Full ONVO Social Stream

Latest ONVO News From Around the Web

Below are the latest news stories about ORGANOVO HOLDINGS INC that investors may wish to consider to help them evaluate ONVO as an investment opportunity.

Organovo Announces FXR Program

Lead Molecule Poised for Phase 2 in IBDSAN DIEGO, March 21, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing novel human therapies with demonstrated function in high fidelity three-dimensional (3D) tissues that recapitulate key aspects of human disease, today announced a clinical program for FXR 314, an FXR agonist that has completed initial clinical trials. FXR314 is a drug with safety and tolerability after da

Yahoo | March 21, 2023

Will Organovo Holdings (NASDAQ:ONVO) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Yahoo | February 10, 2023

Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates

SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional biology (3D biology) company focused on delivering scientific and medical breakthroughs using novel technologies including 3D bioprinting, today announced that it has successfully advanced the use of its first inflammatory bowel disease (IBD) model and has achieved the next milestone, target validation. The company announced in May 2022 that it had achieved a successful Crohn’s disease model

Yahoo | November 15, 2022

Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), an early-stage biotechnology company that is focusing on building high fidelity, 3D tissues that recapitulate key aspects of human disease, today announced that Keith Murphy, Executive Chairman, will participate in the H.C. Wainwright 24th Annual Global Investment Conference, September 12 - 14, 2022. Organovo plans to advance drugs discovered in its cutting-edge human 3D disease models in inflammatory bowel dis

Yahoo | September 6, 2022

Organovo Announces Postponement of Annual Meeting of Stockholders

SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), an early-stage biotechnology company that is focusing on building high fidelity, 3D tissues that recapitulate key aspects of human disease (the “Company”), today announced that its 2022 Annual Meeting of Stockholders (the “2022 Annual Meeting”) that was scheduled to be held at 9:00AM (Pacific Time) on Wednesday, September 7, 2022 has been postponed to October 12, 2022 at 9:00AM (Pacific Time), a date determined

Yahoo | September 6, 2022

Read More 'ONVO' Stories Here

ONVO Price Returns

1-mo -10.94%
3-mo -6.56%
6-mo 0.59%
1-year -24.34%
3-year -86.43%
5-year -93.80%
YTD 21.28%
2022 -61.16%
2021 -70.49%
2020 72.90%
2019 -62.95%
2018 -28.36%

Continue Researching ONVO

Here are a few links from around the web to help you further your research on Organovo Holdings Inc's stock as an investment opportunity:

Organovo Holdings Inc (ONVO) Stock Price | Nasdaq
Organovo Holdings Inc (ONVO) Stock Quote, History and News - Yahoo Finance
Organovo Holdings Inc (ONVO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!